Clone:
REA591
Type of antibody:
Recombinant antibodies, Primary antibodies
Isotype:
recombinant human IgG1

Specifications for Anti-TCRγ/δ antibodies

Overview

REA591 recognizes the human γ/δ T cell receptor (TCR). The T cell receptor is a heterodimeric glycoprotein associated with the CD3 antigen. It consists of a α and a β chain (TCRα/β) or a γ and a δ chain (TCRγ/δ). The γ and δ TCR chains are composed of constant and variable regions, each encoded by distinct gene segments. The γ chain forms either disulfide-linked or non-disulfide–linked heterodimers with the δ-subunit. The γ/δ T cell receptor is present on a subset of T lymphocytes in peripheral blood. TCRγ/δ is involved in the antigen recognition of tumor-associated antigens or bacterial antigens presented by MHC class I molecules.
Additional information: Clone REA591 displays negligible binding to Fc receptors.

Applications

Reagent can be used for immunophenotyping by flow cytometry. Abnormal numbers of cells expressing this antigen or aberrant expression levels of the antigen can be expected in some disease states. It is important to understand the normal expression pattern for this antigen and its relationship to expression of other relevant antigens in order to perform appropriate analysis.
Expression of TCRγ/δ may be used as aid to diagnostic in the characterization of samples from individuals suspected with hematologic neoplasia.

Detailed product information

Technical specifications

CloneREA591
Isotyperecombinant human IgG1
Type of antibodyRecombinant antibodies, Primary antibodies
Specieshuman
AntigenTCRγ/δ
Distribution of antigenT cells

Resources for Anti-TCRγ/δ antibodies

Certificates

Please follow this
link
to download the Certificate of Conformity (CoC) by lot number.

References for Anti-TCRγ/δ antibodies

Publications

  1. Airoldi, I. et al. (2015)
    γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ
    +
    /CD19
    +
    lymphocytes.
    Blood 125(15): 2349-2358
  2. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
  3. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
  4. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
  5. Bonneville, M. et al. (2010) Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10(7): 467-478
  6. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
  7. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition
  8. Wiest, D. L. (2016) Development of γδ T cells, the special-force soldiers of the immune system. Methods Mol. Biol. 1323: 23-32